Daljit Singh Aurora - 08 Jan 2026 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Title: Chief Operating and Development Officer
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora
Issuer symbol
NMRA
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 16:19:28 UTC
Previous filing
13 Nov 2025
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aurora Daljit Singh Title: Chief Operating and Development Officer C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL WAY, SUITE 1, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora 09 Jan 2026 0001793971

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Award $0 +750,000 $0.000000 750,000 08 Jan 2026 Common Stock 750,000 $2.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Operating and Development Officer